對於KRAS基因突變型的結腸直腸癌患者的抗腫瘤劑和治療效果預測方法

• 收藏
• 分享

专利权人:

Taiho Pharmaceutical Co. Ltd.

发明人:

ITO, Masanobu,伊藤雅信,OKABE, Hiroyuki,岡部博之

申请号：

HK14110619.4

公开号：

HK1197086B

申请日:

2014.10.23

申请国别(地区):

HK

年份:

2017

代理人:

摘要：

This invention provides a method for predicting a therapeutic effect of chemotherapy that uses an antitumor agent comprising ±,±,±-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, the method comprising: (1) detecting the presence or absence of KRAS gene mutation in a biological sample obtained from the patient and (2) predicting that the patient is likely to sufficiently respond to the chemotherapy, when KRAS gene mutation is detected in Step (1).

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/